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Introduction
Iris melanocytoma is an uncommon variant of iris nevus
which may result in pigment dispersion and secondary
glaucoma.1–3 Elevated intraocular pressure (IOP) may
occur either because of obstruction of the trabecular
meshwork by cell debris and pigment from the tumor
or a direct compression effect on the trabecular mesh-
work.4 In addition to local tumor resection, little is
known about the optimal treatment for refractory glau-
coma associated with iris melanocytoma. Here, we
report the long-term effect of diode laser transscleral
cyclophotocoagulation (TSCP) on IOP in 1 such case
after the melanocytoma was excised.
Case Report
A 28-year-old healthy man with blurred vision and
elevated IOP was referred to our department. His visual
acuity was 20/25 in the right eye and 20/20 in the
left. IOP was 40 mmHg in the right eye while on mul-
tiple glaucoma medications and 20 mmHg in the left
eye. In the right eye, a dark brown lobulated irregular-
shaped iris mass was noted between the 4 and 5:30
o’clock positions, touching the pupillary margin and
surrounded by several small pigmented lesions (Figure
1). Gonioscopy showed an open angle covered by dif-
fuse heavy pigmentation, except where it was occu-
pied by the mass. Ultrasound biomicroscopy showed
no involvement of the ciliary body. The optic cup-to-
disc ratio was 0.7. Ocular examination of the left eye
was unremarkable.
The mass and the surrounding lesions were excised
en bloc by sector iridectomy. The tissue was densely
pigmented without cellular detail on hematoxylin and
eosin staining. Bleached sections disclosed plump-
shaped cells with abundant cytoplasm, round nuclei, low
nuclear-to-cytoplasmic ratio, and conspicuous nucleoli
occasionally (Figure 2). There were no mitotic figures
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in all the sections. Postoperatively, topical 1% pred-forte
was administered for 3 weeks. One month after surgery,
IOP had decreased gradually and was under control
for 2 weeks. However, IOP increased to 36 mmHg
despite maximum medical therapy 2 months after sur-
gery. The patient then underwent diode laser TSCP
in his right eye. Ten laser spots were applied from 8 to
2 o’clock with a setting of 2 seconds and 2,000 mW.
One day after laser therapy, slit lamp examination was
remarkable for 4+ cells and 3+ flare, and the patient’s
visual acuity decreased to counting fingers. After top-
ical 1% pred-forte and oral prednisolone, the anterior
chamber inflammatory response decreased to 3+ cells
and 2+ flare 1 week afterwards. Ultrasound B scans
showed a mild vitreous opacity, and his visual acuity
was improved to 0.3. Two weeks later, examination
revealed 1+ cells and 1+ flare, and his vision returned
to 20/20. By 3 weeks after the procedure, IOP had
decreased to 20 mmHg. Postoperative IOP remained
normal without medication at the last follow-up of 
15 months.
Discussion
Secondary glaucoma is uncommon in iris melanocy-
toma. In a series of 47 cases, increased IOP was observed
in only 5 (11%) eyes at the 5-year follow-up visit.3
However, secondary glaucoma may develop rapidly,
respond poorly to glaucoma medication, and lead 
to irreversible optic nerve damage in some cases.5
Although the mechanism of secondary glaucoma in
iris melanocytoma appears to be multifactorial, reduc-
ing IOP is the only recognized method of glaucoma
treatment. Local resection can reduce the tumor bur-
den and allow the trabecular meshwork to recover.1,2
Moreover, excision provides tissue for diagnosis when
malignancy cannot be ruled out. Our case showed 
a transient reduction in IOP after tumor excision.
Unfortunately, the IOP became elevated again 2 months
after surgery. Maximal medical therapy failed to control
IOP and glaucoma surgery became mandatory.
Iris melanocytomas are generally considered benign.
However, occasional malignant transformation of iris
melanocytoma has been reported.6 Nakazawa and
Tamai4 reported 1 case of secondary glaucoma asso-
ciated with iris melanocytoma that was successfully
treated with trabeculectomy combined with biopsy.
Nevertheless, the possibility of malignant transformation
of the lesion and tumor spreading into the extraocular
tissues following filtering surgery cannot be excluded
altogether. Laser trabeculoplasty is theoretically con-
traindicated because it carries the risk of tumor cells
spreading. Ciliary body destruction is another surgical
alternative. TSCP can be achieved by laser applications
ab externo without globe invasion. However, compli-
cations such as phthisis bulbi, sympathetic ophthalmia
and malignant glaucoma have been reported.7,8 There
are few studies on the effect of TSCP on secondary
glaucoma associated with intraocular tumor.9 In our
case, TSCP was performed 180 degrees in the supe-
rior temporal half away from the tumor’s location to
reduce the risk of tumor spreading. After TSCP, IOP
decreased to normal without affecting visual acuity.
In conclusion, this is the first report of a favorable
outcome with diode laser TSCP in the management
of intractable glaucoma caused by iris melanocytoma.
Diode laser TSCP can be a safe option for such patients
after local excision of iris melanocytoma.
Figure 1. Right eye shows a dark brown lobulated iris lesion
located between the 4 and 5:30 o’clock positions with pupillary
margin involvement.
Figure 2. Bleached section of the iris lesion (hematoxylin & eosin,
100×) shows plump-shaped cells with abundant cytoplasm and
round nuclei with low nuclear-to-cytoplasmic ratio. Conspicuous
nucleoli are occasionally noted (arrow). There were no mitotic figures
in all the sections.
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